Although targeted MAPK pathway inhibition has achieved remarkable patient responses in many cancers, the development of resistance has remained a critical challenge. Adaptive tumor response underlies

Figshare2021-12-03 更新50

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

IDH突变肿瘤耐药

靶向治疗耐药

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

NIAID Data Ecosystem30

Suppression of adaptive responses to targeted cancer therapy by transcriptional repression [RNA-seq]

靶向治疗耐药

转录抑制联合疗法

Large-scale genomic profiling efforts have facilitated the characterization of molecular alterations in cancers and aided the development of targeted kinase inhibitors for a wide array of cancer types

NIAID Data Ecosystem50

The phosphatase PTPRG controls FGFR1 activity and influences sensitivity to FGFR kinase inhibitors

靶向治疗耐药

FGF信号通路调控

Recently, FGFR1 has been found to be overexpressed in osteosarcoma and thus represents an important target for precision medicine. However, because targeted cancer therapy based on FGFR inhibitors has

NIAID Data Ecosystem30

Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins

资源简介：

相关数据集